Adjuvant early and late cardioprotective therapy: access to the heart
R Hinkel, P Boekstegers, C Kupatt - Cardiovascular research, 2012 - academic.oup.com
Coronary heart disease is still the leading cause of death in industrialized nations, occurring
either as acute coronary occlusion and myocardial infarction or as chronic ischaemic …
either as acute coronary occlusion and myocardial infarction or as chronic ischaemic …
Autologus transplantation of mononuclear bone marrow cells after acute myocardial infarction: a PILOT study
FS Angeli, PRA Caramori… - International …, 2012 - internationaljournalofcardiology.com
[4] Xu J, Cui G, Esmailian F, et al. Atrial extracellular matrix remodeling and the maintenance
of atrial fibrillation. Circulation 2004; 109: 363–8.[5] Marchlinski FE, Callans DJ, Gottlieb CD …
of atrial fibrillation. Circulation 2004; 109: 363–8.[5] Marchlinski FE, Callans DJ, Gottlieb CD …
[HTML][HTML] Cardiovascular repair with bone marrow-derived cells
While bone marrow (BM)-derived cells have been comprehensively studied for their
propitious pre-clinical results, clinical trials have shown controversial outcomes. Unlike …
propitious pre-clinical results, clinical trials have shown controversial outcomes. Unlike …
Cardiac repair—fact or fancy?
E Leontiadis, A Manginas, DV Cokkinos - Heart failure reviews, 2006 - Springer
Patients with ischemic cardiomyopathy have a poor prognosis despite all pharmacological,
interventional and surgical treatment modalities currently applied. Heart transplantation …
interventional and surgical treatment modalities currently applied. Heart transplantation …
Long-term outcome of intra-myocardial injection of autologous bone marrow mononuclear cells combined with isolated coronary artery bypass grafting for patients …
R Wang, L Zhang, Y Wang, Z Gong… - The Heart Surgery …, 2016 - journal.hsforum.com
Objective: This study aimed to investigate whether intra-myocardial injection of autologous
bone marrow mononuclear cells (aBMMNCs) into peri-scarred myocardium during coronary …
bone marrow mononuclear cells (aBMMNCs) into peri-scarred myocardium during coronary …
[PDF][PDF] Interval estimation of the overall treatment effect in random-effects meta-analyses comparing frequentist, Bayesian, and bootstrap methods: recommendations …
F Weber, Ä Glass, G Kundt, G Knapp… - Research Synthesis …, 2020 - files.de-1.osf.io
There exists a variety of interval estimators for the overall treatment effect in a random-effects
meta-analysis. A recent literature review summarizing existing methods suggested that in …
meta-analysis. A recent literature review summarizing existing methods suggested that in …
Safety and efficacy of direct cardiac shockwave therapy in patients with ischemic cardiomyopathy undergoing coronary artery bypass grafting (the CAST-HF trial) …
F Nägele, L Pölzl, M Graber, J Hirsch, A Mayr… - Trials, 2022 - Springer
Background Coronary artery disease (CAD) remains a severe socio-economic burden in the
Western world. Coronary obstruction and subsequent myocardial ischemia result in the …
Western world. Coronary obstruction and subsequent myocardial ischemia result in the …
Фракция выброса и размеры левого желудочка сердца после интракоронарного введения аутологичных мононуклеарных клеток костного мозга у больных с …
СН Бурнос, АС Немков, СА Белый… - … хирургии имени ИИ …, 2011 - cyberleninka.ru
Трансплантация клеток костного мозга тивное лечение. Кроме того, в основной группе
исходное значение фракции выброса было снижено у 53 пациентов, а в контрольной …
исходное значение фракции выброса было снижено у 53 пациентов, а в контрольной …
Surgical intramyocardial stem cell therapy for chronic ischemic heart failure
A Kaminski, P Donndorf, C Klopsch, G Steinhoff - Herz, 2010 - Springer
Die Therapie der chronisch-ischämischen Herzkrankheit mit Stammzellen aus dem
Knochenmark wird im Rahmen klinischer Studien und als Therapieversuch weltweit bereits …
Knochenmark wird im Rahmen klinischer Studien und als Therapieversuch weltweit bereits …